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Positron emission tomography (PET)/computed tomography (CT), which combines the
advantages of high sensitivity and specificity of PET and high resolution of CT, is a unique
tool for cancer management. PET/CT has been widely used in cancer diagnosis and treat-
ment. The article reviews the recent applications of PET/CT in radiation oncology, with a
focus on 18F-fluorodeoxyglucose (FDG)-PET/CT, addressing the applications in treatment
planning and treatment response assessment of radiation therapy.
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INTRODUCTION
With high sensitivity and specificity, positron emission tomogra-
phy (PET) is playing an important role in cancer imaging and
treatment (Histed et al., 2012; Sveistrup et al., 2012). Combin-
ing with computed tomography (CT), PET can provide valuable
information on tumor extent for most cancers (Ling et al., 2000).
PET/CT has been successfully used in the diagnosis, initial stag-
ing, and response assessment in various malignant tumors with
high diagnostic accuracy (Borst et al., 2005; Eschmann et al., 2006;
Facey et al., 2007) and has been used for PET-guided radiation
treatment planning (Jarritt et al., 2006; Gregoire et al., 2007). 18F-
fluorodeoxyglucose (FDG) is the only Medicare approved PET/CT
tracer for cancer imaging and FDG-PET/CT is the most widely
available PET/CT procedure used in daily oncology practice. Stud-
ies have shown that FDG-PET/CT improves staging accuracy,
with a 20–30% improvement in specificity and sensitivity over
CT scanning (Toloza et al., 2003; Rodríguez Fernández et al.,
2007; Yi et al., 2008). PET/CT systems offer a unique opportu-
nity of improving target localization and facilitating treatment
planning for radiation therapy. The advent of integrated or hybrid
PET/CT scanners, which has facilitated hardware fusion of PET
and CT data sets and improves the accuracy of target localiza-
tion as compared to the procedures using software fusion of PET
and CT scans acquired on separate scanners, have been used pop-
ularly nowadays. This study is to review the recent applications
of PET/CT in radiation oncology, i.e., in radiation treatment
response assessment and treatment planning, with a focus on
FDG-PET/CT.
PET/CT FOR RADIATION TREATMENT PLANNING
Positron emission tomography/CT has been increasingly applied
for target delineation in radiation treatment planning for a vari-
ety of cancer treatments, e.g., cervix, lung, head and neck (HN),
and prostate, etc. (Erdi et al., 2002; Bradley et al., 2004; Lavrenkov
et al., 2005; Nestle et al., 2005; Paulino et al., 2005; Greco et al.,
2007; Lin et al., 2007; van Baardwijk et al., 2007; Dolezelova et al.,
2008; Henriques de Figueiredo et al., 2009; MacManus et al., 2009;
Yu et al., 2009; De Jong et al., 2010; Terezakis et al., 2011; Lee et al.,
2012).
Studies showed that FDG-PET/CT improved the accuracy of
target definition (Nestle et al., 2006; MacManus et al., 2009)
and PET/CT reduced the inter-observer variability compared to
CT alone (Tejwani et al., 2012). PET/CT helps in finding CT-
undetected or borderline sized nodes and improves target accuracy
for nodal radiation. For lung cancer, PET/CT showed high sen-
sitivity and specificity for mediastinal lymph node involvement
over CT. FDG-PET/CT can be used to differentiate tumor from
collapsed lung and normal tissue, and defines disease extent in
the chest wall. Studies had showed the differences of volumes
contoured based on PET/CT and those contoured based on CT
alone. For HN cancer, PET/CT can identify metastatic nodal dis-
ease which CT cannot. Studies have showed significant differences
between PET/CT-derived and CT-derived tumor volumes in HN
patients. Garg et al.’s (2012) study showed that PET/CT led to
modification in treatment planning in 55% of the HN patients
studied. For cervical cancer, PET/CT has showed high sensitiv-
ity and specificity in initial staging and restaging cervical cancer
and PET/CT has the advantage of detecting gross para-aortic
and pelvic lymph nodes (PLNs) for treatment planning, which
CT may not be able to detect. Incorporation of PET/CT into
radiotherapy planning has the potential to allow radiation-dose
escalation without increasing side effects (De Ruysscher et al.,
2005; Pinkawa et al., 2012). Radiation treatment can be improved
by using PET/CT for target volume delineation: doses to the tumor
can be increased and organs at risk (OARs) can be spared. A sum-
mary of PET/CT applications in radiation treatment planning is
provided in Table 1.
Positron emission tomography/CT images are used in two ways
in radiation treatment planning: for PET/CT images acquired
from a diagnostic scanner, the images are registered/fused with
planning CT images; for PET/CT images acquired on a ded-
icated planning PET/CT scanner, the images are directly used
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Table 1 | Application of PET/CT in radiation treatment planning.
Reference Site of tumor Results/Conclusion
Dolezelova et al.
(2008)
Cervix (external
beam and HDR)
PET/CT plays an important role in diagnosis and treatment of cervical carcinoma and in determination of
target volumes
Lin et al. (2007) Cervix (LDR and
HDR)
FDG-PET/CT-based treatment planning allowed for improved dose coverage of the tumor without
significantly increasing the dose to the bladder and rectum
Tejwani et al. (2012) Cervix Inter-observer GTV variability decreased in PET/CT-based planning compared to CT-based planning
Paulino et al. (2005) Head and neck PET/CT-based GTVs were different from CT-based GTVs in most cases
Henriques de
Figueiredo et al.
(2009)
Head and neck Volume comparison showed a reduction and qualitative discrepancies between the PET- and CT-volumes
Garg et al. (2012) Head and neck PET/CT led to a modification in treatment planning in 55% of patients studied
De Jong et al.
(2010)
Prostate Review of PET/CT and radiotherapy in prostate cancer patients
Pinkawa et al.
(2012)
Prostate Treatment planning with (18)F-choline PET-CT allows a dose escalation to a macroscopic intraprostatic lesion
without significantly increasing toxicity
Terezakis et al.
(2011)
Lymphoma PET/CT-based treatment planning for lymphoma patients resulted in considerable changes in management,
volume definition, and normal tissue dosimetry
Yeoh and Mikhaeel
(2013)
Lymphoma Critical review of incorporating PET/CT into radiation therapy of lymphoma
Erdi et al. (2002) NSCLC There was a change in PTV outline based on CT images versus CT/PET fused images
Bradley et al.
(2004)
NSCLC Biologic targeting with PET alters the radiation treatment volume significantly in 30–60% of NSCLC
patients for whom definitive therapy is planned
Greco et al. (2007) NSCLC Significant impact of PET-derived contours on treatment planning was shown in 30–60% of the plans with
respect to the CT-only target volume
van Baardwijk et al.
(2007)
NSCLC Source-to-background ratio-based auto-delineation showed a good correlation with pathology, decreased
the delineated volumes of the GTVs, and reduced the inter-observer variability
Nestle et al. (2005) NSCLC Different techniques of tumor contour definition by (18)F-FDG-PET in radiotherapy planning lead to
substantially different volumes
Yu et al. (2009) NSCLC Integrated 18F-FDG-PET/CT is an effective tool to define the target of GTV in radiotherapy
Lavrenkov et al.
(2005)
NSCLC PET results in a reduction in the CT-derived GTV for NSCLC primary target volume in 15% of the patients
De Ruysscher et al.
(2005)
NSCLC The use of a combined dedicated PET/CT allowed significant radiation-dose escalation whilst respecting all
relevant normal tissue constraints
Nestle et al. (2006) NSCLC Review of technical factors influencing PET and PET/CT data, and their consequences for radiotherapy
planning
Lee et al. (2012) Lung Review of FDG-PET/CT-based radiation treatment planning for lung cancer
Treatments using brachytherapy are indicated.
for treatment planning. To register/fuse the diagnostic PET/CT
images acquired in non-treatment position, with planning CT
images acquired in treatment position, software for image reg-
istration/fusion are needed. Usually rigid image registration
is performed. Rigid image registration accounts for only lin-
ear or uniform transformation within six degrees of freedom.
Recently, deformable registration which can account for signif-
icant temporal and anatomic changes between the image sets,
has been applied for PET/CT-CT image fusion. The study of
Kovalchuk et al. (2012) has demonstrated that deformable reg-
istration is a powerful tool for the image fusion of diagnos-
tic PET/CT and planning CT for target volume delineation.
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Table 2 | Application of PET/CT in radiation treatment response.
Reference Site of tumor Results/Conclusion
Bussink et al.
(2011)
Various (Review) Discussion of the potential of integrated PET-CT for treatment selection, response monitoring
early after the start of treatment, and prediction of outcome for solid tumors
Caldarella et al.
(2012)
Osteosarcoma Review of FDG-PET/CT in assessing response to neoadjuvant treatment in patients with osteosarcoma
Cheebsumon et al.
(2012)
NSCLC PET-based tumor delineation methods provided tumor sizes in agreement with pathology
Choi et al. (2002) NSCLC Correlation between the gradient of residual metabolic rate of glucose after chemoradiotherapy and the
probability of tumor control on the basis of pathologic tumor response is an inverse dose-response
relationship
Grigsby et al.
(2004)
Cervix Post-therapy abnormal FDG uptake (persistent or new) as detected by whole-body PET measures tumor
response and might be predictive of tumor recurrence and death from cervical cancer
Hicks et al. (2004) NSCLC Post-radiotherapy inflammatory changes detected by FDG-PET are positively correlated with tumor
response
Hicks (2005) Various (Review) The potential benefits and limitations of FDG-PET were discussed
Huh et al. (2012) Rectum The FDG-PET/CT parameters and the response index may be best for assessing the neoadjuvant
chemoradiation response of locally advanced rectal cancer
Janssen et al.
(2012)
Rectum The presented predictive model could be used to select patients to be considered for less invasive surgical
interventions or even a “wait and see” policy
Jeong et al. (2002) NSCLC (18)F-FDG uptake correlated with survival in NSCLC
Juweid and
Cheson (2006)
Various (Review) The use of 18F-FDG-PET in the assessment of cancer after therapy, including restaging tumors
and monitoring tumor response, was discussed
Kalff et al. (2006) Rectum Post-chemoradiation (18)F-FDG-PET scintigraphy provides good medium-term prognostic information in
patients with advanced rectal cancer undergoing radical surgery with curative intent
Kidd et al. (2010) Cervix SUV is a prognostic biomarker, predicting treatment response, pelvic recurrence risk, and disease-specific
survival
Lee et al. (2013) Cervix Significant decreases in tumor volume were observed on PET/CT images during and after concurrent
chemoradiotherapy
Perez et al. (2012) Rectum Assessment of tumor response at 12 weeks after chemoradiation completion with PET/CT imaging may
provide a useful additional tool with good overall accuracy for the selection of patients
Petit et al. (2009) NSCLC A methodology was presented to derive relationships between FDG uptake, dose, and metabolic control
Porceddu et al.
(2011)
Head and neck PET-directed management of the neck after definitive RT in node-positive HNSCC appropriately spares neck
dissections in patients with PET-negative residual CT nodal abnormalities
Pöttgen et al.
(2006)
NSCLC SUV values from two serial PET/CT scans, before and after three chemotherapy cycles or later, allow
prediction of histopathologic response in the primary tumor and mediastinal lymph nodes and have
prognostic value
Rege et al. (2000) Head and neck Pretreatment PET findings may have prognostic implications in determining which patients will achieve
long-term local control with primary radiation therapy
Vaidya et al. (2012) NSCLC Multimodality image-feature modeling provides better performance compared to existing metrics and holds
promise for individualizing radiotherapy planning
van Loon et al.
(2011)
SCLC Both early CT and FDG-metabolic tumor volume changes show a significant correlation with survival in
SCLC
van Stiphout et al.
(2011)
Rectum The model and the nomogram developed based on clinical and sequential PET-CT data can accurately
predict pathologic complete response
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The use of dedicated PET/CT systems for treatment planning is
increasing in radiation oncology. The advantage is that the system
produces co-registered images with the patient in the treatment
position and the images can be used directly for treatment plan-
ning without image fusion with another planning CT. Thus the
accuracy of target volume delineation is improved.
For target volume delineation on PET/CT images, manual or
automated method is used. It is challenging to identify lesion
edges in noisy PET data. The manual delineation relies on clin-
ician’s expertise and is also limited by image display settings,
e.g., window level and width. The automated delineation is
based on quantitative or semi-quantitative techniques derived
from the standardized uptake value (SUV), which assesses the
level of FDG uptake. The basic idea is to decide a cutoff of
measured SUV to separate target from background tissues. Var-
ious techniques of automated delineation have been studied
(Lee, 2010). There are concerns of the accuracy of automated
delineation. Yeoh and Mikhaeel’s (2013) paper emphasized that
one must be cautious when adopting automated volume delin-
eation using PET/CT information because there can be signif-
icant variation depending on the parameters and segmentation
techniques used.
A limiting factor for accurate target volume delineation by
PET/CT is organ and tumor motion caused by patient respiration.
Respiration introduces artifacts in CT and PET images, which can
result in degraded image quality and can lead to possible tumor
missing from treatment volumes or under-treatment. Methods
have been developed for motion management in PET/CT for radi-
ation treatment planning, which include 4D PET/CT and deep
inspiration breath-holding PET/CT (Nehmeh et al., 2004, 2007;
Bettinardi et al., 2012; Scripes and Yaparpalvi, 2012).
PET/CT FOR TREATMENT RESPONSE ASSESSMENT
18F-fluorodeoxyglucose-PET/CT has been frequently used to
monitor the response of cancer treatment (Rege et al., 2000; Choi
et al., 2002; Jeong et al., 2002; Hicks et al., 2004; Hicks, 2005;
Gagel et al., 2006; Juweid and Cheson, 2006; Pöttgen et al., 2006;
Bussink et al., 2011; Porceddu et al., 2011; Caldarella et al., 2012;
Cheebsumon et al., 2012; Huh et al., 2012; Janssen et al., 2012;
Perez et al., 2012; Vaidya et al., 2012; Lee et al., 2013). Studies
have demonstrated the potential of using FDG to predict response
and survival in different cancer sites (Grigsby et al., 2004; Hicks
et al., 2004; Kalff et al., 2006; Petit et al., 2009; van Loon et al.,
2011; van Stiphout et al., 2011). Kidd et al. (2010) evaluated the
prognostic significance of the maximum SUV(max) of FDG in a
study of 83 cervical cancer patients. In the study, the SUV(PLN)
was analyzed for its association with treatment response, pelvic
disease recurrence, disease-specific survival, and overall survival.
The SUV(PLN) was found to be correlated with an increased
risk of persistent disease after treatment (P = 0.0025), specifi-
cally within the PLN region (P = 0.0003), and was found to be
predictive of an increased risk of ever developing pelvic disease
recurrence (P = 0.0035). Patients with a higher SUV(PLN) were
found to have significantly worse disease-specific (P = 0.0230) and
overall survival (P = 0.0378). The study showed that SUV(PLN)
is a prognostic biomarker, which can predict treatment response,
pelvic recurrence risk, and disease-specific survival in patients with
cervical cancer. A summary of PET/CT applications in radiation
treatment response is provided in Table 2.
A study has demonstrated that a high SUV for FDG in the pri-
mary tumor and regional nodes after completion of radiotherapy
predicted poor treatment response and tumor control in non-
small cell lung cancer (Jeong et al., 2002). Rege et al.’s (2000) study
in HN patients showed that PET findings might have prognostic
implications in determining which patients will achieve long-term
local control with primary radiation therapy and might help iden-
tify those patients at increased risk of recurrence that may benefit
from more aggressive altered fractionation schemes or combined
modality therapy. Jeong et al.’s (2002) study showed that the
detection of residual and recurrent disease by FDG-PET/CT has a
reported sensitivity of 100%, specificity of 92%, positive predictive
value of 92%, negative predictive value of 100%, and diagnostic
accuracy of 96%.
A recent study enrolling 50 patients with locally advanced rec-
tal cancer assessed the value of sequential FDG-PET/CT scans
for predicting the response of locally advanced rectal cancer to
neoadjuvant chemoradiation (Huh et al., 2012). The treatment
consisted of concurrent chemoradiation, which included preop-
erative 5-fluorouracil-based chemotherapy and pelvic radiation
(4500 to 5040 cGy). All the patients underwent FDG-PET/CT
before and 5 weeks later (median: 35 d) after the completion of
chemoradiation. After chemoradiation, 32 of 50 patients (64%)
were classified as responders according to the tumor regres-
sion grade. For all the patients, the mean pre-chemoradiation
SUV(max) was significantly higher than the mean SUV(max)
value at post-chemoradiation (P < 0.001). The mean response
index was significantly higher in the responders than that in the
non-responder patients (P = 0.001). The study concluded that
the FDG-PET/CT parameters and especially the mean response
index, may be best for assessing the neoadjuvant chemoradia-
tion response of locally advanced rectal cancer and those val-
ues can potentially assist physicians for planning the optimal
treatment.
CONCLUSION
Positron emission tomography/CT is being actively used in radia-
tion oncology for treatment response assessment and treatment
planning. Careful attention needs to be paid to the details in
applications, e.g., image fusion, automated image segmentation,
and patient motion management. PET/CT, a valuable tool for
radiation oncology, is bringing significant impact on radiation
treatment.
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